https://www.selleckchem.com/products/dzd9008.html
It needs to be tailored to the patient's functional status, comorbid diseases, prognosis, and response to conservative management.Background To account for cancer heterogeneity, we previously introduced the concept of "personalized" tumor markers, which are biomarkers that are informative in subsets of patients or even a single patient. Recent developments in various multiplex protein technologies create excitement for the discovery of markers of tumor burden in individual patients, but the reliability of the technologies remains to be
Like
Comment
Share
